26.34
+1.14(+4.52%)
Currency In USD
| Previous Close | 25.2 |
| Open | 25.5 |
| Day High | 26.64 |
| Day Low | 24.87 |
| 52-Week High | 35 |
| 52-Week Low | 18.35 |
| Volume | 86,971 |
| Average Volume | 47,055 |
| Market Cap | 315.21M |
| PE | -36.08 |
| EPS | -0.73 |
| Moving Average 50 Days | 24.95 |
| Moving Average 200 Days | 25.93 |
| Change | 1.14 |
If you invested $1000 in XOMA Corporation (XOMA) 10 years ago, it would be worth $351.2 as of July 01, 2025 at a share price of $26.34. Whereas If you bought $1000 worth of XOMA Corporation (XOMA) shares 5 years ago, it would be worth $1,371.16 as of July 01, 2025 at a share price of $26.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
GlobeNewswire Inc.
Jun 27, 2025 11:30 AM GMT
EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
GlobeNewswire Inc.
May 27, 2025 12:01 PM GMT
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the d
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire Inc.
May 07, 2025 11:30 AM GMT
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speak